SciELO - Scientific Electronic Library Online

 
vol.42 número1Descripción de las caracteristicas clínicas de las neoplasias mieloproliferativas crónicas (NMPC). Primer informe del registro colombiano de NMPC índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Acta Medica Colombiana

versión impresa ISSN 0120-2448

Resumen

MOLINA, Olga; AMARILES, Pedro  y  ANGULO, Nancy. List of drug tracers/ markers as a tool in pharmacotherapeutic follow-up or drug-safety programs. Acta Med Colomb [online]. 2017, vol.42, n.1, pp.42-54. ISSN 0120-2448.

Introduction:

negative outcomes associated with medication (NOM), including adverse drug reactions (ADRs) or safety problems, are a relevant clinical problem due to their high incidence and harmful effects on health. A drug could be considered a tracer / marker because of: 1) an increased likelihood of causing ADR or safety problems; or 2) its use to treat and therefore identify patients with ADR. Tracer drug listings could be useful in pharmacological safety or pharmacotherapeutic monitoring programs.

Objective:

the objective of this study was to structure a list of drug tracer / markers of the patients with the highest risk of presenting NOM, which could be useful to select patients for FFT or pharmacological safety programs.

Data collection:

initially, a structured review was performed in PubMed / Medline to identify drugs associated with the presentation of ADRs classified as severe or moderate and with a prevalence of 10% or greater. Subsequently, the list of identified medications was compared and complemented with high alert medications of the Institute for Safe Medication Practices (ISMP) and medications used to treat ADRs or antidotes.

Results:

a general listing of 139 drug tracers / markers was generated.

Conclusions:

this listing could be a tool to detect and select the patients who could most benefit from the FTS or pharmacological safety programs. Studies designed to evaluate the practical usefulness of this listing are required.

Palabras clave : high alert drugs; pharmaco-safety progRAM; pharmacovigilance; drug tracers; pharmacotherapeutic monitoring; medication errors.

        · resumen en Español     · texto en Español     · Español ( pdf )